Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Nuvectis Pharma (NASDAQ: NVCT) Raises $93 Million in $20 Stock Offering

• Nuvectis Pharma (NASDAQ: NVCT) priced 5,000,000 shares at $20.00 per share in a firm commitment offering.

Vinay Lochav | 01 July 2026

Oramed Pharmaceuticals (NASDAQ: ORMP) Overhauls Bylaws, Extends Scilex Debt Deadline

• Oramed Pharmaceuticals (NASDAQ: ORMP) approved amended bylaws simplifying stockholder consent procedures under Delaware law.

Vinay Lochav | 01 July 2026

Perrigo (NYSE: PRGO) Expands Board With Consumer and Retail Veterans

• Perrigo Company plc (NYSE: PRGO) expands its board from eight to ten members with two new independent directors.

Vinay Lochav | 01 July 2026

BioAffinity Technologies (NASDAQ: BIAF) Reports Surge in CyPath Lung Sales Amid Expansion

• BioAffinity Technologies reported a significant increase in CyPath Lung test sales, indicating rising demand.

Vinay Lochav | 01 July 2026

Celularity (NASDAQ: CELU) Secures $1 Million Insider Trust Loan, 4% Fixed Rate

• Celularity (NASDAQ: CELU) received a $1 million loan from an insider trust linked to the Barach family.

Vinay Lochav | 01 July 2026

Catalyst Pharmaceuticals (NASDAQ: CPRX) Announces Topline Phase 1 Results for AGAMREE

• Catalyst Pharmaceuticals issued a press release on June 30 2026 announcing topline data from a two‑part Phase 1 study of AGAMREE (vamorolone).

Vinay Lochav | 01 July 2026

Gossamer Bio (NASDAQ: GOSS) Sets $0.19 Conversion Price for 2030 Notes

• Gossamer Bio Inc. (NASDAQ: GOSS) established an initial conversion rate of 5,347.5936 shares per $1,000 principal for its 7.50% convertible notes due 2030.

Vinay Lochav | 01 July 2026

IBio Obesity Drug IBIO- (NYSE American: IBIO)610 Cuts Activin E by 98% in Primate Study

• IBio’s IBIO-610 reduced active Activin E levels by 98% at week 4 in obese non-human primates after a single dose.

Vinay Lochav | 01 July 2026

INmune Bio (NASDAQ: INMB) Inc. Adjusts Warrant Terms to Boost Investor Participation

• INmune Bio Inc. (NASDAQ: INMB) reduces the exercise price of certain warrants to $1.40, down from $1.95.

Vinay Lochav | 01 July 2026

Ardent Health (NYSE: ARDT) Announces Leadership Transition Following CEO Departure

• Martin J. Bonick has officially stepped down from his role as President and CEO of Ardent Health, effective June 2, 2026.

Vinay Lochav | 01 July 2026
Support

Hi! How can we help you today?

Loading…